Skip to search formSkip to main contentSkip to account menu

eltrombopag

Known as: Eltrombopagum, eltrombopag [Chemical/Ingredient] 
An orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the platelet… 
National Institutes of Health

Related topics

Related topics

18 relations

Broader (3)

BenzoatesHydrazinesPyrazoles
Breast Cancer Resistance Protein Inhibitors [MoA]Eltrombopag olamineMPL protein, humanThrombopoietin Receptor Agonists [MoA]

Narrower (3)

PromactaRevoladeSB-497115-GR

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial
Patients with inherited thrombocytopenias often require platelet transfusions to raise their platelet count before surgery or… 
Review
2018
Review
2018
Eltrombopag for use in children with immune thrombocytopenia.
Eltrombopag is currently the only US Food and Drug Administration-approved thrombopoietin receptor agonist for the treatment of… 
Highly Cited
2016
Highly Cited
2016
Revealing eltrombopag’s promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation
Eltrombopag is a small, non-peptide thrombopoietin mimetic that has been approved for increasing platelet count not only in… 
Highly Cited
2015
Highly Cited
2015
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.
UNLABELLED Because Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT) patients have microthrombocytopenia… 
Highly Cited
2014
Highly Cited
2014
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
Eltrombopag is effective and safe in immune thrombocytopenia (ITP). Some patients may sustain their platelet response when… 
Highly Cited
2014
Highly Cited
2014
Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults.
Immune thrombocytopenia (ITP) results from platelet destruction and production suppression. Eltrombopag belongs to a new class of… 
Highly Cited
2013
Highly Cited
2013
Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists
Thrombopoietin receptor agonists (TRAs) are effective treatments for immune thrombocytopenia (ITP). However, continuous therapy… 
Highly Cited
2012
Highly Cited
2012
Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.
Eltrombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been approved recently for the… 
Review
2011
Review
2011
Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
n engl j med 365;8 nejm.org august 25, 2011 734 This Journal feature begins with a case vignette that includes a therapeutic… 
Highly Cited
2009
Highly Cited
2009
Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Thrombocytopenia is a frequent symptom and clinical challenge in patients with myelodysplastic syndrome (MDS) and acute myeloid… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)